Key Segments:
By Isotope Type
-
Actinium-225
-
Radium-223
-
Lead-212
-
Bismuth-213
-
Others
By Therapy Type
-
Radioligand Therapy
-
Radioimmunotherapy
-
Diagnostic & Theranostic Use
By Indication
-
Prostate Cancer
-
Neuroendocrine Tumors
-
Leukemia & Hematologic Malignancies
-
Bone Metastases
-
Others
By End User
-
Hospitals & Cancer Treatment Centers
-
Specialty Oncology Clinics & Radiopharmacies
-
Research & Academic Institutes
Regional Coverage:
North America
-
U.S.
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Isotope Type X Indication)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Targeted Alpha Therapy Market is expected to grow at a CAGR of approximately 24.9% from 2026 to 2035, based on triangulated secondary research estimates.
The Targeted Alpha Therapy Market was valued at approximately USD 1,245.30 Million in 2025, based on triangulation across multiple independent research sources.
The major growth factor is the expanding late-stage clinical pipeline of actinium-225 and lead-212 labeled radioligands, rising PSMA-targeted radioligand adoption, and growing regulatory support for alpha-emitter radiopharmaceuticals.
The Radium-223 segment dominated the Targeted Alpha Therapy Market by isotope type, representing the largest share of revenue in 2025.
North America dominated the Targeted Alpha Therapy Market in 2025, holding an estimated 42.60% share of total global market revenue.
Asia Pacific is expected to register the fastest CAGR of approximately 28.30% from 2026 to 2035, driven by expanding clinical trial infrastructure and rising radiopharmaceutical manufacturing investment.